ALS

From Wikipedia the free encyclopedia

Amyotrophic lateral sclerosis
Other names
Diagram of a human nervous system highlighting the brain, spinal cord, motor neurons, and muscles of the body affected by ALS
Parts of the nervous system affected by ALS, causing progressive symptoms in skeletal muscles throughout the body[2]
SpecialtyNeurology
SymptomsEarly: Stiff muscles, muscle twitches, gradual increasing weakness[3]
Later: Difficulty in speaking, swallowing, and breathing; respiratory failure[3] 10–15% experience frontotemporal dementia[2]
ComplicationsFalling (accident); Respiratory failure; Pneumonia; Malnutrition
Usual onset45–75 years[2]
CausesUnknown (about 85%), genetic (about 15%)
Risk factorsGenetic risk factors; age; male sex; heavy metals; organic chemicals; smoking; electric shock; physical exercise; head injury[2]
Diagnostic methodClinical diagnosis of exclusion based on progressive symptoms of upper and lower motor neuron degeneration in which no other explanation can be found. Supportive evidence from electromyography, genetic testing, and neuroimaging
Differential diagnosisMultifocal motor neuropathy, Kennedy's disease, Hereditary spastic paraplegia, Nerve compression syndrome, Diabetic neuropathy, Post-polio syndrome, Myasthenia gravis, Multiple sclerosis[4]
TreatmentWalker (mobility); Wheelchair; Non-invasive ventilation;[5] Feeding tube; Augmentative and alternative communication; symptomatic management
MedicationRiluzole, Edaravone, Sodium phenylbutyrate/ursodoxicoltaurine, Tofersen, Dextromethorphan/quinidine
PrognosisLife expectancy highly variable but typically 2–4 years after diagnosis[6]
Frequency
  • Incidence: 1.6/100,000 individuals per year[6]
  • Prevalence: 4.4/100,000 living individuals[6]
  • Lifetime risk: 1 in 400 individuals[7]

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease in the United States, is a rare but terminal neurodegenerative disorder that results in the progressive loss of both upper and lower motor neurons that normally control voluntary muscle contraction.[3] ALS is the most common form of the motor neuron diseases.[8] ALS often presents in its early stages with gradual muscle stiffness, twitches, weakness, and wasting.[3] Motor neuron loss typically continues until the abilities to eat, speak, move, and, lastly, breathe are all lost.[3] While only 15% of people with ALS also fully develop frontotemporal dementia, an estimated 50% face at least some minor difficulties with thinking and behavior.[9] Depending on which of the aforementioned symptoms develops first, ALS is classified as limb-onset (begins with weakness in the arms or legs) or bulbar-onset (begins with difficulty in speaking or swallowing).[10]

Most cases of ALS (about 90% to 95%) have no known cause, and are known as sporadic ALS.[3][11] However, both genetic and environmental factors are believed to be involved.[12] The remaining 5% to 10% of cases have a genetic cause, often linked to a history of the disease in the family, and these are known as familial ALS (hereditary).[6][13] About half of these genetic cases are due to disease-causing variants in one of four specific genes.[14] The diagnosis is based on a person's signs and symptoms, with testing conducted to rule out other potential causes.[3]

There is no known cure for ALS.[3] The goal of treatment is to slow the disease progression, and improve symptoms.[9] Treatments that slow ALS include riluzole (extends life by two to three months) and sodium phenylbutyrate/ursodoxicoltaurine (extends life by around seven months).[15][16] Non-invasive ventilation may result in both improved quality, and length of life.[5] Mechanical ventilation can prolong survival but does not stop disease progression.[17] A feeding tube may help maintain weight and nutrition.[18] Death is usually caused by respiratory failure.[19] The disease can affect people of any age, but usually starts around the age of 60.[19] The average survival from onset to death is two to four years, though this can vary, and about 10% of those affected survive longer than ten years.[20]

Descriptions of the disease date back to at least 1824 by Charles Bell.[21] In 1869, the connection between the symptoms and the underlying neurological problems was first described by French neurologist Jean-Martin Charcot, who in 1874 began using the term amyotrophic lateral sclerosis.[21]

Classification[edit]

ALS is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body.[3] Other motor neuron diseases include primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy, pseudobulbar palsy, and monomelic amyotrophy (MMA).[22]

As a disease, ALS itself can be classified in a few different ways: by which part of the motor neurons are affected; by the parts of the body first affected; whether it is genetic; and the age at which it started. Each individual diagnosed with the condition will sit at a unique place at the intersection of these complex and overlapping subtypes, which presents a challenge to diagnosis, understanding, and prognosis.[23]

Subtypes of motor neuron disease[edit]

Classic ALS involves neurons in the brain and spinal cord (upper motor neurons, highlighted red), as well as the lower motor neurons, which go from the spinal cord to the muscles, highlighted teal.[24]

ALS can be classified by the types of motor neurons that are affected.[2] To successfully control any voluntary muscle in the body, a signal must be sent from the motor cortex in the brain down the upper motor neuron as it travels down the spinal cord. There, it connects via a synapse to the lower motor neuron which connects to the muscle itself. Damage to either the upper or lower motor neuron, as it makes its way from the brain to muscle, causes different types of symptoms.[24] Damage to the upper motor neuron typically causes spasticity including stiffness and increased tendon reflexes, and/or clonus, while damage to the lower motor neuron typically causes weakness, muscle atrophy, and fasciculations.[25]

Classical, or classic ALS, involves degeneration to both the upper motor neurons in the brain and the lower motor neurons in the spinal cord.[6][2] Primary lateral sclerosis (PLS) involves degeneration of only the upper motor neurons, and progressive muscular atrophy (PMA) involves only the lower motor neurons. There is debate over whether PLS and PMA are separate diseases or simply variants of ALS.[9]

Main ALS Subtypes Upper motor neuron degeneration Lower motor neuron degeneration
Classical ALS Yes Yes
Primary lateral sclerosis (PLS) Yes No
Progressive muscular atrophy (PMA) No Yes

Classical ALS accounts for about 70% of all cases of ALS and can be subdivided into where symptoms first appear as these are usually focussed to one region of the body at initial presentation before later spread. Limb-onset ALS (also known as spinal-onset) and bulbar-onset ALS.[9] Limb-onset ALS begins with weakness in the hands, arms, feet, and/or legs[10] and accounts for about two-thirds of all classical ALS cases.[9] Bulbar-onset ALS begins with weakness in the muscles of speech, chewing, and swallowing[24] and accounts for about 25% of classical ALS cases.[6] A rarer type of classical ALS affecting around 3% of patients is respiratory-onset,[9] in which the initial symptoms are difficulty breathing (dyspnea) upon exertion, at rest, or while lying flat (orthopnea).[26]

Primary lateral sclerosis (PLS) is a subtype of the overall ALS category which accounts for about 5% of all cases and only affects the upper motor neurons in the arms, legs, and bulbar region.[27] However, more than 75% of people with apparent PLS go on to later develop lower motor neuron signs within four years of symptom onset, meaning that a definitive diagnosis of PLS cannot be made until several years have passed.[28] PLS has a better prognosis than classical ALS, as it progresses slower, results in less functional decline, does not affect the ability to breathe, and causes less severe weight loss than classical ALS.[27]

Progressive muscular atrophy (PMA) is another subtype that accounts for about 5% of the overall ALS category and affects lower motor neurons in the arms, legs, and bulbar region.[27] While PMA is associated with longer survival on average than classical ALS, it is still progressive over time, eventually leading to respiratory failure and death.[9] As with PLS developing into classical ALS, PMA can also develop into classical ALS over time if the lower motor neuron involvement progresses to include upper motor neurons, in which case the diagnosis might be changed to classic ALS.[28]

Rare isolated variants of ALS[edit]

Isolated variants of ALS have symptoms that are limited to a single region for at least a year; they progress more slowly than classical ALS and are associated with longer survival.[2] These regional variants of ALS can only be considered as a diagnosis should the initial symptoms fail to spread to other spinal cord regions for an extended period of time (at least 12 months).[29] Flail arm syndrome is characterized by lower motor neuron damage affecting the arm muscles, typically starting with the upper arms symmetrically and progressing downwards to the hands.[2] Flail leg syndrome is characterized by lower motor neuron damage leading to asymmetrical weakness and wasting in the legs starting around the feet.[2] Isolated bulbar palsy is characterized by upper or lower motor neuron damage in the bulbar region (in the absence of limb symptoms for at least 20 months),[30] leading to gradual onset of difficulty with speech (dysarthria) and swallowing (dysphagia).

Illustration showing the range of upper and lower motor neuron involvement in the two most common types of ALS (top row) and three of the most common rare subtypes of ALS (bottom row)

Age of onset[edit]

ALS can also be classified based on the age of onset. While the peak age of onset is 58 to 63 for sporadic ALS and 47 to 52 for genetic ALS,[19] about 10% of all cases of ALS begin before age 45 ("young-onset" ALS), and about 1% of all cases begin before age 25 ("juvenile" ALS).[24] People who develop young-onset ALS are more likely to be male, less likely to have bulbar onset of symptoms, and more likely to have a slower progression of the disease.[28] Juvenile ALS is more likely to be genetic in origin than adult-onset ALS; the most common genes associated with juvenile ALS are FUS, ALS2, and SETX.[31] Although most people with juvenile ALS live longer than those with adult-onset ALS, some of them have specific mutations in FUS and SOD1 that are associated with a poor prognosis.[32] Late onset (after age 65) is generally associated with a more rapid functional decline and shorter survival.[33]

Signs and symptoms[edit]

The disorder causes muscle weakness, atrophy, and muscle spasms throughout the body due to the degeneration of the upper motor and lower motor neurons. Sensory nerves and the autonomic nervous system are generally unaffected, meaning the majority of people with ALS maintain hearing, sight, touch, smell, and taste.[3]

Initial symptoms[edit]

The start of ALS may be so subtle that the symptoms are overlooked.[3] The earliest symptoms of ALS are muscle weakness or muscle atrophy, typically on one side of the body. Other presenting symptoms include trouble swallowing or breathing, cramping, or stiffness of affected muscles; muscle weakness affecting an arm or a leg; or slurred and nasal speech. The parts of the body affected by early symptoms of ALS depend on which motor neurons in the body are damaged first.[34]

In limb-onset ALS, the first symptoms are in the arms or the legs. If the legs are affected first, people may experience awkwardness, tripping, or stumbling when walking or running; this is often marked by walking with a "dropped foot" that drags gently on the ground. If the arms are affected first, they may experience difficulty with tasks requiring manual dexterity, such as buttoning a shirt, writing, or turning a key in a lock.[35]

In bulbar-onset ALS, the first symptoms are difficulty speaking or swallowing. Speech may become slurred, nasal in character, or quieter. There may be difficulty with swallowing and loss of tongue mobility. A smaller proportion of people experience "respiratory-onset" ALS, where the intercostal muscles that support breathing are affected first.[19]

Over time, people experience increasing difficulty moving, swallowing (dysphagia), and speaking or forming words (dysarthria). Symptoms of upper motor neuron involvement include tight and stiff muscles (spasticity) and exaggerated reflexes (hyperreflexia), including an overactive gag reflex.[24] While the disease does not cause pain directly, pain is a symptom experienced by most people with ALS caused by reduced mobility.[36] Symptoms of lower motor neuron degeneration include muscle weakness and atrophy, muscle cramps, and fleeting twitches of muscles that can be seen under the skin (fasciculations).[25]

Progression[edit]

Although the initial site of symptoms and subsequent rate of disability progression vary from person to person, the initially affected body region is usually the most affected over time, and symptoms usually spread to a neighbouring body region. For example, symptoms starting in one arm usually spread next to either the opposite arm or to the leg on the same side.[24] Bulbar-onset patients most typically get their next symptoms in their arms rather than legs, arm-onset patients typically spreads to the legs before the bulbar region, and leg-onset patients typically spread to the arms rather than the bulbar region.[37] Over time, regardless of where symptoms began, most people eventually lose the ability to walk or use their hands and arms independently. Less consistently, they may lose the ability to speak and to swallow food. It is the eventual development of weakness of the respiratory muscles, with the loss of ability to cough and to breathe without support, that is ultimately life-shortening in ALS.[5]

The rate of progression can be measured using the ALS Functional Rating Scale - Revised (ALSFRS-R), a 12-item instrument survey administered as a clinical interview or self-reported questionnaire that produces a score between 48 (normal function) and 0 (severe disability).[38] The ALSFRS-R is the most frequently used outcome measure in clinical trials[39] and is used by doctors to track disease progression.[40] Though the degree of variability is high and a small percentage of people have a much slower progression, on average people with ALS lose about 1 ALSFRS-R point per month.[41] Brief periods of stabilization ("plateaus") and even small reversals in ALSFRS-R score are not uncommon, due to the fact the tool is subjective, can be affected by medication, and different forms of compensation for changes in function.[42] However, it is rare (<1%) for these improvements to be large (i.e. greater than 4 ALSFRS-R points) or sustained (i.e. greater than 12 months).[42] A survey-based study among clinicians showed that they rated a 20% change in the slope of the ALSFRS-R as being clinically meaningful, which is the most common threshold used to determine whether a new treatment is working in clinical trials.[43]

Late stage disease management[edit]

Difficulties with chewing and swallowing make eating very difficult (dysphagia) and increase the risk of choking or of aspirating food into the lungs.[44] In later stages of the disorder, aspiration pneumonia can develop, and maintaining a healthy weight can become a significant problem that may require the insertion of a feeding tube.[44] As the diaphragm and intercostal muscles of the rib cage that support breathing weaken, measures of lung function such as vital capacity and inspiratory pressure diminish. In respiratory-onset ALS, this may occur before significant limb weakness is apparent. Individuals affected by the disorder may ultimately lose the ability to initiate and control all voluntary movement,[5] known as locked-in syndrome. Bladder and bowel function are usually spared, meaning urinary and fecal incontinence are uncommon, although trouble getting to a toilet can lead to difficulties. The extraocular muscles responsible for eye movement are usually spared,[45] meaning the use of eye tracking technology to support augmentative communication is often feasible, albeit slow, and needs may change over time.[46] Despite these challenges, many people in an advanced state of disease report satisfactory wellbeing and quality of life.[47]

Prognosis, staging, and survival[edit]

Although respiratory support using non-invasive ventilation can ease problems with breathing and prolong survival,[48] it does not affect the progression rate of ALS. Most people with ALS die between two and four years after the diagnosis.[5] Around 50% of people with ALS die within 30 months of their symptoms beginning, about 20% live between five and ten years,[19] and about 10% survive for 10 years or longer.[20]

The most common cause of death among people with ALS is respiratory failure, often accelerated by pneumonia.[19] Most ALS patients die at home after a period of worsening difficulty breathing, a decline in their nutritional status, or a rapid worsening of symptoms.[49] Sudden death or acute respiratory distress are uncommon.[50] Access to palliative care is recommended from an early stage to explore options, ensure psychosocial support for the patient and caregivers, and to discuss advance healthcare directives.[49]

As with cancer staging, ALS has staging systems numbered between 1 and 4 that are used for research purposes in clinical trials.[6] Two very similar staging systems emerged around a similar time, the King's staging system and Milano-Torino (MiToS) functional staging.[51]

Kings ALS staging system and prognosis at each stage
Stage 1 Stage 2 Stage 3 Stage 4
Stage description Symptom onset, involvement of the first region 2A: Diagnosis

2B: Involvement of the second region

Involvement of the third region 4A: Need for a feeding tube

4B: Need for non-invasive ventilation

Median time to stage 13.5 months 17.7 months 23.3 months 4A: 17.7 months

4B: 30.3 months

MiToS ALS staging system and prognosis at each stage
Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Stage description No loss of a functional domain Loss of 1 domain Loss of 2 domains Loss of 3 domains Loss of 4 domains Death
Probability of death at each stage 7% 26% 33% 33% 86%

Providing individual patients with a precise prognosis is not currently possible, though research is underway to provide statistical models on the basis of prognostic factors including age at onset, progression rate, site of onset, and presence of frontotemporal dementia.[6] Those with a bulbar onset have a worse prognosis than limb-onset ALS; a population-based study found that bulbar-onset ALS patients had a median survival of 2.0 years and a 10-year survival rate of 3%, while limb-onset ALS patients had a median survival of 2.6 years and a 10-year survival rate of 13%.[52] Those with respiratory-onset ALS had a shorter median survival of 1.4 years and 0% survival at 10 years.[52] While astrophysicist Stephen Hawking lived for 55 more years following his diagnosis, his was an unusual case.[53]

Cognitive, emotional, and behavioral symptoms[edit]

Cognitive impairment or behavioral dysfunction is present in 30–50% of individuals with ALS,[54] and can appear more frequently in later stages of the disease.[55] Language dysfunction, executive dysfunction, and troubles with social cognition and verbal memory are the most commonly reported cognitive symptoms in ALS.[55] Cognitive impairment is found more frequently in patients with C9orf72 gene repeat expansions, bulbar onset, bulbar symptoms, family history of ALS, and/or a predominantly upper motor neuron phenotype.[56]

Emotional lability is a symptom in which patients cry, smile, yawn, or laugh, either in the absence of emotional stimuli, or when they are feeling the opposite emotion to that being expressed;[57] it is experienced by about half of ALS patients and is more common in those with bulbar-onset ALS.[5] While relatively benign relative to other symptoms, it can cause increased stigma and social isolation as people around the patient struggle to react appropriately to what can be frequent and inappropriate outbursts in public.[58]

In addition to mild changes in cognition that may only emerge during neuropsychological testing, around 10–15% of individuals have signs of frontotemporal dementia (FTD).[5] Repeating phrases or gestures, apathy, and loss of inhibition are the most frequently reported behavioral features of ALS.[59] ALS and FTD are now considered to be part of a common disease spectrum (ALS–FTD) because of genetic, clinical, and pathological similarities.[60] Genetically, repeat expansions in the C9orf72 gene account for about 40% of genetic ALS and 25% of genetic FTD.[61]

Cognitive and behavioral issues are associated with poorer prognosis as they may reduce adherence to medical advice, and deficits in empathy and social cognition which may increase caregiver burden.[62]

Cause[edit]

It is not known what causes sporadic ALS, hence it is described as an idiopathic disease.[19] Though its exact cause is unknown, genetic and environmental factors are thought to be of roughly equal importance.[12] The genetic factors are better understood than the environmental factors; no specific environmental factor has been definitively shown to cause ALS. A multi-step liability threshold model for ALS proposes that cellular damage accumulates over time due to genetic factors present at birth and exposure to environmental risks throughout life.[63] ALS can strike at any age, but its likelihood increases with age.[64] Most people who develop ALS are between the ages of 40 and 70, with an average age of 55 at the time of diagnosis.[65] ALS is 20% more common in men than women,[65] but this difference in sex distribution is no longer present in patients with onset after age 70.[64]

Genetics and genetic testing[edit]

While they appear identical clinically and pathologically,[66] ALS can be classified as being either familial or sporadic, depending on whether there is a known family history of the disease and/or whether an ALS-associated genetic mutation has been identified via genetic testing.[67] Familial ALS is thought to account for 10–15% of cases overall and can include monogenic, oligogenic, and polygenic modes of inheritance.[14]

There is considerable variation among clinicians on how to approach genetic testing in ALS, and only about half discuss the possibility of genetic inheritance with their patients, particularly if there is no discernible family history of the disease.[68] In the past, genetic counseling and testing was only offered to those with obviously familial ALS.[14] But it is increasingly recognized that cases of sporadic ALS may also be due to disease-causing de novo mutations in SOD1, or C9orf72,[69] an incomplete family history, or incomplete penetrance, meaning that a patient's ancestors carried the gene but did not express the disease in their lifetimes.[14] The lack of positive family history may be caused by lack of historical records, having a smaller family, older generations dying earlier of causes other than ALS, genetic non-paternity, and uncertainty over whether certain neuropsychiatric conditions (e.g. frontotemporal dementia, other forms of dementia, suicide, psychosis, schizophrenia) should be considered significant when determining a family history.[14] There have been calls in the research community to routinely counsel and test all diagnosed ALS patients for familial ALS,[70] particularly as there is now a licensed gene therapy (tofersen) specifically targeted to carriers of SOD-1 ALS. A shortage of genetic counselors and limited clinical capacity to see such at-risk individuals makes this challenging in practice, as does the unequal access to genetic testing around the world.[71]

More than 40 genes have been associated with ALS, of which four account for nearly half of familial cases, and around 5% of sporadic cases:[14] C9orf72 (40% of familial cases, 7% sporadic), SOD1 (12% of familial cases, 1-2% sporadic), FUS (4% of familial cases, 1% sporadic), and TARDBP (4% of familial cases, 1% sporadic), with the remaining genes mostly accounting for fewer than 1% of either familial or sporadic cases.[14] ALS genes identified to date explain the cause of about 70% of familial ALS and about 15% of sporadic ALS.[14] Overall, first-degree relatives of an individual with ALS have a ~1% risk of developing ALS themselves.[14]

Environmental and other factors[edit]

The multi-step hypothesis suggests the disease is caused by some interaction between an individual's genetic risk factors and their cumulative lifetime of exposures to environmental factors, termed their exposome.[14] The most consistent lifetime exposures associated with developing ALS (other than genetic mutations) include heavy metals (e.g. lead and mercury), chemicals (e.g. pesticides and solvents), electric shock, physical injury (including head injury), and smoking (in men more than women).[72] Overall these effects are small, with each exposure in isolation only increasing the likelihood of a very rare condition by a small amount. For instance an individual's lifetime risk of developing ALS might go from "1 in 400" without an exposure to between "1 in 300" and "1 in 200" if they were exposed to heavy metals.[72] A range of other exposures have weaker evidence supporting them and include participation in professional sports, having a lower body mass index, lower educational attainment, manual occupations, military service, exposure to Beta-N-methylamino-L-alanin (BMAA), and viral infections.[72]

Although some personality traits, such as openness,[73] agreeableness[74] and conscientiousness[74] appear remarkably common among patients with ALS, it remains open whether personality can increase susceptibility to ALS directly.[75] Instead, genetic factors giving rise to personality might simultaneously predispose people to developing ALS,[73] or the above personality traits might underlie lifestyle choices which are in turn risk factors for ALS.[74]

Pathophysiology[edit]

Neuropathology[edit]

Upon examination at autopsy, features of the disease that can be seen with the naked eye include skeletal muscle atrophy, motor cortex atrophy, sclerosis of the corticospinal and corticobulbar tracts, thinning of the hypoglossal nerves (which control the tongue), and thinning of the anterior roots of the spinal cord.[10]

The defining feature of ALS is the death of both upper motor neurons (located in the motor cortex of the brain) and lower motor neurons (located in the brainstem and spinal cord).[76] In ALS with frontotemporal dementia, neurons throughout the frontal and temporal lobes of the brain die as well.[77] The pathological hallmark of ALS is the presence of inclusion bodies (abnormal aggregations of protein) known as Bunina bodies in the cytoplasm of motor neurons. In about 97% of people with ALS, the main component of the inclusion bodies is TDP-43 protein;[10] however, in those with SOD1 or FUS mutations, the main component of the inclusion bodies[78][79] is SOD1 protein or FUS protein, respectively.[24] Prion-like propagation of misfolded proteins from cell to cell may explain why ALS starts in one area and spreads to others.[24] The glymphatic system may also be involved in the pathogenesis of ALS.[80]

Biochemistry[edit]

This figure shows ten proposed disease mechanisms for ALS and the genes associated with them.[81]

It is still not fully understood why neurons die in ALS, but this neurodegeneration is thought to involve many different cellular and molecular processes.[9] The genes known to be involved in ALS can be grouped into three general categories based on their normal function: protein degradation, the cytoskeleton, and RNA processing.[82] Mutant SOD1 protein forms intracellular aggregations that inhibit protein degradation. Cytoplasmic aggregations of wild-type (normal) SOD1 protein are common in sporadic ALS.[77] It is thought that misfolded mutant SOD1 can cause misfolding and aggregation of wild-type SOD1 in neighboring neurons in a prion-like manner.[10] Other protein degradation genes that can cause ALS when mutated include VCP, OPTN, TBK1, and SQSTM1. Three genes implicated in ALS that are important for maintaining the cytoskeleton[77] and for axonal transport[10] include DCTN1, PFN1, and TUBA4A.[77]

There are a number of ALS genes that encode for RNA-binding proteins. The first to be discovered was TDP-43 protein,[77] a nuclear protein that aggregates in the cytoplasm of motor neurons in almost all cases of ALS; however, mutations in TARDBP, the gene that codes for TDP-43, are a rare cause of ALS.[10] FUS codes for FUS, another RNA-binding protein with a similar function to TDP-43, which can cause ALS when mutated.[61] It is thought that mutations in TARDBP and FUS increase the binding affinity of the low-complexity domain, causing their respective proteins to aggregate in the cytoplasm.[83] Once these mutant RNA-binding proteins are misfolded and aggregated, they may be able to misfold normal proteins both within and between cells in a prion-like manner.[77] This also leads to decreased levels of RNA-binding protein in the nucleus, which may mean that their target RNA transcripts do not undergo normal processing. Other RNA metabolism genes associated with ALS include ANG, SETX, and MATR3.[10]

C9orf72 is the most commonly mutated gene in ALS and causes motor neuron death through a number of mechanisms.[77] The pathogenic mutation is a hexanucleotide repeat expansion (a series of six nucleotides repeated over and over);[84] people with up to 30 repeats are considered normal, while people with hundreds or thousands of repeats can have familial ALS, frontotemporal dementia, or sometimes sporadic ALS.[85] The three mechanisms of disease associated with these C9orf72 repeats are deposition of RNA transcripts in the nucleus, translation of the RNA into toxic dipeptide repeat proteins in the cytoplasm, and decreased levels of the normal C9orf72 protein.[77] Mitochondrial bioenergetic dysfunction leading to dysfunctional motor neuron axonal homeostasis (reduced axonal length and fast axonal transport of mitochondrial cargo) has been shown to occur in C9orf72-ALS using human induced pluripotent stem cell (iPSC) technologies coupled with CRISPR/Cas9 gene-editing, and human post-mortem spinal cord tissue examination.[86]

Excitotoxicity, or nerve cell death caused by high levels of intracellular calcium due to excessive stimulation by the excitatory neurotransmitter glutamate, is a mechanism thought to be common to all forms of ALS. Motor neurons are more sensitive to excitotoxicity than other types of neurons because they have a lower calcium-buffering capacity and a type of glutamate receptor (the AMPA receptor) that is more permeable to calcium. In ALS, there are decreased levels of excitatory amino acid transporter 2 (EAAT2), which is the main transporter that removes glutamate from the synapse; this leads to increased synaptic glutamate levels and excitotoxicity. Riluzole, a drug that modestly prolongs survival in ALS, inhibits glutamate release from pre-synaptic neurons; however, it is unclear if this mechanism is responsible for its therapeutic effect.[10]

Diagnosis[edit]

An MRI of the brain (axial FLAIR) looking at a person as if from above that shows increased T2 signal as a small white region within the posterior part of the internal capsule around the center of the image, consistent with the diagnosis of ALS

No single test can provide a definite diagnosis of ALS.[3] Instead, the diagnosis of ALS is primarily based on the symptoms and signs the physician observes in the person and a series of tests to rule out other diseases.[3] Physicians obtain the person's full medical history and usually conduct a neurologic examination at regular intervals to assess whether signs and symptoms such as muscle weakness, atrophy of muscles, hyperreflexia, Babinski's sign, and spasticity are worsening.[3] A number of biomarkers are being studied for the condition, but as of 2023 are not in general medical use.[87]

An MRI of the brain looking at a person from side-on that shows increased T2 signal as a white region in the posterior part of the internal capsule that can be tracked to the motor cortex, consistent with the diagnosis of ALS

Differential diagnosis[edit]

Because symptoms of ALS can be similar to those of a wide variety of other, more treatable diseases or disorders, appropriate tests must be conducted to exclude the possibility of other conditions. One of these tests is electromyography (EMG), a special recording technique that detects electrical activity in muscles. Certain EMG findings can support the diagnosis of ALS. Another common test measures nerve conduction velocity (NCV).[88] Specific abnormalities in the NCV results may suggest, for example, that the person has a form of peripheral neuropathy (damage to peripheral nerves) or myopathy (muscle disease) rather than ALS. While a magnetic resonance imaging (MRI) is often normal in people with early-stage ALS, it can reveal evidence of other problems that may be causing the symptoms, such as a spinal cord tumor, multiple sclerosis, a herniated disc in the neck, syringomyelia, or cervical spondylosis.[3]

Based on the person's symptoms and findings from the examination and from these tests, the physician may order tests on blood and urine samples to eliminate the possibility of other diseases, as well as routine laboratory tests. In some cases, for example, if a physician suspects the person may have a myopathy rather than ALS, a muscle biopsy may be performed.[3]

A number of infectious diseases can sometimes cause ALS-like symptoms,[3] including human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), Lyme disease, and syphilis.[9] Neurological disorders such as multiple sclerosis, post-polio syndrome, multifocal motor neuropathy, CIDP, spinal muscular atrophy, and spinal and bulbar muscular atrophy can also mimic certain aspects of the disease and should be considered.[3]

ALS must be differentiated from the "ALS mimic syndromes", which are unrelated disorders that may have a similar presentation and clinical features to ALS or its variants.[89] Because the prognosis of ALS and closely related subtypes of motor neuron disease are generally poor, neurologists may carry out investigations to evaluate and exclude other diagnostic possibilities. Disorders of the neuromuscular junction, such as myasthenia gravis (MG) and Lambert–Eaton myasthenic syndrome, may also mimic ALS, although this rarely presents diagnostic difficulty over time.[90][91] Benign fasciculation syndrome and cramp fasciculation syndrome may also, occasionally, mimic some of the early symptoms of ALS. Nonetheless, the absence of other neurological features that develop inexorably with ALS means that, over time, the distinction will not present any difficulty to the experienced neurologist; where doubt remains, EMG may be helpful.[92]

Management[edit]

There is no cure for ALS.[9] Management focuses on treating symptoms and providing supportive care, with the goal of improving quality of life and prolonging survival.[9] This care is best provided by multidisciplinary teams of healthcare professionals; attending a multidisciplinary ALS clinic is associated with longer survival, fewer hospitalizations, and improved quality of life.[5]

Non-invasive ventilation (NIV) is the main treatment for respiratory failure in ALS.[10] In people with normal bulbar function, it prolongs survival by about seven months and improves quality of life. One study found that NIV is ineffective for people with poor bulbar function[93] while another suggested that it may provide a modest survival benefit.[9] Many people with ALS have difficulty tolerating NIV.[94] Invasive ventilation is an option for people with advanced ALS when NIV is not enough to manage their symptoms.[5] While invasive ventilation prolongs survival, disease progression and functional decline continue.[17] It may decrease the quality of life of people with ALS or their caregivers.[18][17] Invasive ventilation is more commonly used in Japan than in North America or Europe.[95]

Person with ALS and their assistive technologies
A person with late-stage ALS with a range of assistive technologies to support movement (power wheelchair), breathing (invasive ventilation), and communication (eye tracker and computer)

Physical therapy can promote functional independence[96][97] through an aerobic, range of motion, and stretching exercises.[98] Occupational therapy can assist with activities of daily living through adaptive equipment.[99] Speech therapy can assist people with ALS who have difficulty speaking.[97] Preventing weight loss and malnutrition in people with ALS improves both survival and quality of life.[9] Initially, difficulty swallowing (dysphagia) can be managed by dietary changes and swallowing techniques. A feeding tube should be considered if someone with ALS loses 5% or more of their body weight or if they cannot safely swallow food and water.[10] The feeding tube is usually inserted by percutaneous endoscopic gastrostomy (PEG). There is weak evidence that PEG tubes improve survival.[100] PEG insertion is usually performed with the intent of improving quality of life.[18]

Palliative care should begin shortly after someone is diagnosed with ALS.[101] Discussion of end-of-life issues gives people with ALS time to reflect on their preferences for end-of-life care and can help avoid unwanted interventions or procedures. Hospice care can improve symptom management at the end of life and increases the likelihood of a peaceful death.[18] In the final days of life, opioids can be used to treat pain and dyspnea, while benzodiazepines can be used to treat anxiety.[17]

Medications[edit]

Disease-slowing treatments[edit]

Chemical structure of riluzole, a medication that prolongs survival by 2–3 months[102]

Riluzole has been found to modestly prolong survival by about 2–3 months.[103][102] It may have a greater survival benefit for those with bulbar-onset ALS.[102] It may work by decreasing release of the excitatory neurotransmitter glutamate from pre-synaptic neurons.[10] The most common side effects are nausea and a lack of energy (asthenia).[102] People with ALS should begin treatment with riluzole as soon as possible following their diagnosis.[101] Riluzole is available as a tablet, liquid, or dissolvable oral film.[15]

Edaravone has been shown to modestly slow the decline in function in a small group of people with early-stage ALS.[104][105] It may work by protecting motor neurons from oxidative stress.[106] The most common side effects are bruising and gait disturbance.[105] Edaravone is available as an intravenous infusion or as an oral suspension.[107]

AMX0035 (Relyvrio) is a combination of sodium phenylbutyrate and taurursodiol, which was initially shown to prolong the survival of patients by an average of six months.[108] Relyvrio was withdrawn by the manufacturer in April 2024[109] following the completion of the Phase 3 PHOENIX trial[110] which did not show substantial benefit to ALS patients.

Tofersen (Qalsody) is an antisense oligonucleotide that was approved for medical use in the United States in April 2023, for the treatment of SOD1-associated ALS.[111] In a study of 108 patients with SOD1-associated ALS there was a non-significant trend towards a slowing of progression, as well as a significant reduction in neurofilament light chain,[112] a putative ALS biomarker thought to indicate neuronal damage.[113] A follow-up study and open-label extension suggested that earlier treatment initiation had a beneficial effect on slowing disease progression. Tofersen is available as an intrathecal injection into the lumbar cistern at the base of the spine.[111]

Symptomatic treatments[edit]

Other medications may be used to help reduce fatigue, ease muscle cramps, control spasticity, and reduce excess saliva and phlegm.[98] Gabapentin, pregabalin, and tricyclic antidepressants (e.g., amitriptyline) can be used for neuropathic pain, while nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids can be used for nociceptive pain.[36]

Depression can be treated with selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants,[10] while benzodiazepines can be used for anxiety.[5] There are no medications to treat cognitive impairment/frontotemporal dementia (FTD); however, SSRIs and antipsychotics can help treat some of the symptoms of FTD.[10] Baclofen and tizanidine are the most commonly used oral drugs for treating spasticity; an intrathecal baclofen pump can be used for severe spasticity.[10] Atropine, scopolamine, amitriptyline or glycopyrrolate may be prescribed when people with ALS begin having trouble swallowing their saliva (sialorrhea).[10]

A 2017 review concluded that mexiletine is safe and effective for treating cramps in ALS based on a randomized controlled trial from 2016.[105]

Breathing support[edit]

Non-invasive ventilation[edit]

Non-invasive ventilation supports breathing with a face or nasal mask connected to a ventilator.

Non-invasive ventilation (NIV) is the primary treatment for respiratory failure in ALS[10] and was the first treatment shown to improve both survival and quality of life.[5] NIV uses a face or nasal mask connected to a ventilator that provides intermittent positive pressure to support breathing. Continuous positive pressure is not recommended for people with ALS because it makes breathing more difficult.[17] Initially, NIV is used only at night[5] because the first sign of respiratory failure is decreased gas exchange (hypoventilation) during sleep; symptoms associated with this nocturnal hypoventilation include interrupted sleep, anxiety, morning headaches, and daytime fatigue.[94] As the disease progresses, people with ALS develop shortness of breath when lying down, during physical activity or talking, and eventually at rest.[114] Other symptoms include poor concentration, poor memory, confusion, respiratory tract infections, and a weak cough. Respiratory failure is the most common cause of death in ALS.[5]

It is important to monitor the respiratory function of people with ALS every three months because beginning NIV soon after the start of respiratory symptoms is associated with increased survival. This involves asking the person with ALS if they have any respiratory symptoms and measuring their respiratory function.[5] The most commonly used measurement is upright forced vital capacity (FVC), but it is a poor detector of early respiratory failure and is not a good choice for those with bulbar symptoms, as they have difficulty maintaining a tight seal around the mouthpiece. Measuring FVC while the person is lying on their back (supine FVC) is a more accurate measure of diaphragm weakness than upright FVC.[94] Sniff nasal inspiratory pressure (SNIP) is a rapid, convenient test of diaphragm strength that is not affected by bulbar muscle weakness.[17] If someone with ALS has signs and symptoms of respiratory failure, they should undergo daytime blood gas analysis[5] to look for hypoxemia (low oxygen in the blood) and hypercapnia (too much carbon dioxide in the blood).[17] If their daytime blood gas analysis is normal, they should then have nocturnal pulse oximetry to look for hypoxemia during sleep.[5]

Non-invasive ventilation prolongs survival longer than riluzole.[115] A 2006 randomized controlled trial found that NIV prolongs survival by about 48 days and improves the quality of life; however, it also found that some people with ALS benefit more from this intervention than others. For those with normal or only moderately impaired bulbar function, NIV prolongs survival by about seven months and significantly improves the quality of life. For those with poor bulbar function, NIV neither prolongs survival nor improves the quality of life, though it does improve some sleep-related symptoms.[93] Despite the clear benefits of NIV, about 25–30% of all people with ALS are unable to tolerate it, especially those with cognitive impairment or bulbar dysfunction.[94] Results from a large 2015 cohort study suggest that NIV may prolong survival in those with bulbar weakness, so NIV should be offered to all people with ALS, even if it is likely that they will have difficulty tolerating it.[9]

Invasive ventilation[edit]

Invasive ventilation bypasses the nose and mouth (the upper airways) by making a cut in the trachea (tracheostomy) and inserting a tube connected to a ventilator.[17] It is an option for people with advanced ALS whose respiratory symptoms are poorly managed despite continuous NIV use.[5] While invasive ventilation prolongs survival, especially for those younger than 60, it does not treat the underlying neurodegenerative process. The person with ALS will continue to lose motor function, making communication increasingly difficult and sometimes leading to locked-in syndrome, in which they are completely paralyzed except for their eye muscles.[17] About half of the people with ALS who choose to undergo invasive ventilation report a decrease in their quality of life[18] but most still consider it to be satisfactory. However, invasive ventilation imposes a heavy burden on caregivers and may decrease their quality of life.[17] Attitudes toward invasive ventilation vary from country to country; about 30% of people with ALS in Japan choose invasive ventilation, versus less than 5% in North America and Europe.[95]

Therapy[edit]

A man with ALS communicates with his wife by pointing to letters and words with a head mounted laser pointer.
A man with ALS communicates by pointing to letters and words using a head-mounted laser pointer.

Physical therapy plays a large role in rehabilitation for individuals with ALS. Specifically, physical, occupational, and speech therapists can set goals and promote benefits for individuals with ALS by delaying loss of strength, maintaining endurance, limiting pain, improving speech and swallowing, preventing complications, and promoting functional independence.[96][97]

Occupational therapy and special equipment such as assistive technology can also enhance people's independence and safety throughout the course of ALS.[99] Gentle, low-impact aerobic exercise such as performing activities of daily living, walking, swimming, and stationary bicycling can strengthen unaffected muscles, improve cardiovascular health, and help people fight fatigue and depression. Range of motion and stretching exercises can help prevent painful spasticity and shortening (contracture) of muscles.[116] Physical and occupational therapists can recommend exercises that provide these benefits without overworking muscles because muscle exhaustion can lead to a worsening of symptoms associated with ALS, rather than providing help to people with ALS.[98] They can suggest devices such as ramps, braces, walkers, bathroom equipment (shower chairs, toilet risers, etc.), and wheelchairs that help people remain mobile. Occupational therapists can provide or recommend equipment and adaptations to enable ALS people to retain as much safety and independence in activities of daily living as possible.[99] Since respiratory insufficiency is the primary cause of mortality, physical therapists can help improve respiratory outcomes in people with ALS by implementing pulmonary physical therapy. This includes inspiratory muscle training, lung volume recruitment training, and manual assisted cough therapy aimed at increasing respiratory muscle strength as well as increasing survival rates.[117]

People with ALS who have difficulty speaking or swallowing may benefit from working with a speech-language pathologist.[97] These health professionals can teach people adaptive strategies such as techniques to help them speak louder and more clearly. As ALS progresses, speech-language pathologists can recommend the use of augmentative and alternative communication such as voice amplifiers, speech-generating devices (or voice output communication devices) or low-tech communication techniques such as head-mounted laser pointers, alphabet boards or yes/no signals.[97]

Nutrition[edit]

A gastrostomy tube is placed through the wall of the abdomen into the stomach.

Preventing weight loss and malnutrition in people with ALS improves both survival and quality of life.[9] Weight loss in ALS is caused by muscle wasting, increased resting energy expenditure, and decreased food intake. Difficulty swallowing (dysphagia) develops in about 85% of people with ALS at some point over the course of their disease, leading to malnutrition and weight loss.[17] It is important to regularly assess the weight and swallowing ability of people with ALS.[5] Initially, dysphagia may be managed by dietary changes and modified swallowing techniques.[10] Difficulty swallowing liquids usually develops first and can be managed by switching to thicker liquids like fruit nectar or smoothies, or by adding fluid thickeners to thin fluids like water and coffee. People with ALS should eat soft, moist foods, which tend to be easier to swallow than dry, crumbly, or chewy foods.[114] They should also be instructed on proper head posture during swallowing, which can make swallowing easier.[10] There is tentative evidence that high-calorie diets may prevent further weight loss and improve survival.[105]

A feeding tube should be considered if someone with ALS loses 5% or more of their body weight or if they cannot safely swallow food and water.[10] This can take the form of a gastrostomy tube, in which a tube is placed through the wall of the abdomen into the stomach, or (less commonly) a nasogastric tube, in which a tube is placed through the nose and down the esophagus into the stomach.[17] A gastrostomy tube is more appropriate for long-term use[5] than a nasogastric tube, which is uncomfortable and can cause esophageal ulcers.[17] The feeding tube is usually inserted by a percutaneous endoscopic gastrostomy procedure (PEG).

There is weak evidence that PEG tubes improve survival.[100] PEG insertion is usually performed with the intent of improving quality of life[18] by sustaining nutrition and medication intake.[5] This makes up for reduced oral food intake,[5] decreases risk of weight loss and dehydration, and can decrease anxiety by shortening what can become extended time taken to eat at mealtimes.[18]

End-of-life care[edit]

Palliative care, which relieves symptoms and improves the quality of life without treating the underlying disease, should begin shortly after someone is diagnosed with ALS.[101] Early discussion of end-of-life issues gives people with ALS time to reflect on their preferences for end-of-life care and can help avoid unwanted interventions or procedures.[18] Once they have been fully informed about all aspects of various life-prolonging measures, they can fill out advance directives indicating their attitude toward noninvasive ventilation, invasive ventilation, and feeding tubes.[105] Late in the disease course, difficulty speaking due to muscle weakness (dysarthria) and cognitive dysfunction may impair their ability to communicate their wishes regarding care.[10] Continued failure to solicit the preferences of the person with ALS may lead to unplanned and potentially unwanted emergency interventions, such as invasive ventilation. If people with ALS or their family members are reluctant to discuss end-of-life issues, it may be useful to use the introduction of gastrostomy or noninvasive ventilation as an opportunity to bring up the subject.[18]

Hospice care, or palliative care at the end of life, is especially important in ALS because it helps to optimize the management of symptoms and increases the likelihood of a peaceful death.[18] It is unclear exactly when the end-of-life phase begins in ALS, but it is associated with significant difficulty moving, communicating, and, in some cases, thinking.[10] Although many people with ALS fear choking to death (suffocating),[18] they can be reassured that this occurs rarely, less than 1% of the time.[118] Most patients die at home,[18] and in the final days of life, opioids can be used to treat pain and dyspnea, while benzodiazepines can be used to treat anxiety.[17]

Epidemiology[edit]

ALS is the most common motor neuron disease in adults and the third most common neurodegenerative disease[61] after Alzheimer's disease and Parkinson's disease.[119] Worldwide the number of people who develop ALS yearly is estimated to be 1.9 people per 100,000 per year, while the number of people who have ALS at any given time is estimated to be about 4.5 people per 100,000.[120] In Europe, the number of new cases a year is about 2.6 people per 100,000, while the number affected is 7–9 people per 100,000.[121] The lifetime risk of developing ALS is 1:350 for European men and 1:400 for European women. Men have a higher risk mainly because spinal-onset ALS is more common in men than women.[63] The number of those with ALS in the United States in 2015 was 5.2 people per 100,000, and was higher in whites, males, and people over 60 years old.[122] The number of new cases is about 0.8 people per 100,000 per year in east Asia and about 0.7 people per 100,000 per year in south Asia. About 80% of ALS epidemiology studies have been conducted in Europe and the United States, mostly in people of northern European descent.[10] There is not enough information to determine the rates of ALS in much of the world, including Africa, parts of Asia, India, Russia, and South America.[63] There are several geographic clusters in the Western Pacific where the prevalence of ALS was reported to be 50–100 times higher than the rest of the world, including Guam, the Kii Peninsula of Japan, and Western New Guinea. The incidence in these areas has decreased since the 1960s;[1] the cause remains unknown.[63]

Estimated prevalence of ALS in the United States by age group, 2012–2015[122]

People of all races and ethnic backgrounds may be affected by ALS,[122] but it is more common in whites than in Africans, Asians, or Hispanics.[123] In the United States in 2015, the prevalence of ALS in whites was 5.4 people per 100,000, while the prevalence in blacks was 2.3 people per 100,000. The Midwest had the highest prevalence of the four US Census regions with 5.5 people per 100,000, followed by the Northeast (5.1), the South (4.7), and the West (4.4). The Midwest and Northeast likely had a higher prevalence of ALS because they have a higher proportion of whites than the South and West.[122] Ethnically mixed populations may be at a lower risk of developing ALS; a study in Cuba found that people of mixed ancestry were less likely to die from ALS than whites or blacks.[124] There are also differences in the genetics of ALS between different ethnic groups; the most common ALS gene in Europe is C9orf72, followed by SOD1, TARDBP, and FUS, while the most common ALS gene in Asia is SOD1, followed by FUS, C9orf72, and TARDBP.[125]

ALS can affect people at any age,[54] but the peak incidence is between 50 and 75 years[9] and decreases dramatically after 80 years.[19] The reason for the decreased incidence in the elderly is unclear. One thought is that people who survive into their 80s may not be genetically susceptible to developing ALS; alternatively, ALS in the elderly might go undiagnosed because of comorbidities (other diseases they have), difficulty seeing a neurologist, or dying quickly from an aggressive form of ALS.[124] In the United States in 2015, the lowest prevalence was in the 18–39 age group, while the highest prevalence was in the 70–79 age group.[122] Sporadic ALS usually starts around the ages of 58 to 63 years, while genetic ALS starts earlier, usually around 47 to 52 years.[19] The number of ALS cases worldwide is projected to increase from 222,801 in 2015 to 376,674 in 2040, an increase of 69%. This will largely be due to the aging of the world's population, especially in developing countries.[123]

History[edit]

The French neurologist Jean-Martin Charcot coined the term amyotrophic lateral sclerosis in 1874.[21]
American baseball player Lou Gehrig. In some countries, especially the United States, ALS is called "Lou Gehrig's disease".[126]

Descriptions of the disease date back to at least 1824 by Charles Bell.[21] In 1850, François-Amilcar Aran was the first to describe a disorder he named "progressive muscular atrophy", a form of ALS in which only the lower motor neurons are affected.[127] In 1869, the connection between the symptoms and the underlying neurological problems were first described by Jean-Martin Charcot, who initially introduced the term amyotrophic lateral sclerosis in his 1874 paper.[21] Flail arm syndrome, a regional variant of ALS, was first described by Alfred Vulpian in 1886. Flail leg syndrome, another regional variant of ALS, was first described by Pierre Marie and his student Patrikios in 1918.[128]

Diagnostic criteria[edit]

In the 1950s, electrodiagnostic testing (EMG) and nerve conduction velocity (NCV) testing began to be used to evaluate clinically suspected ALS. In 1969 Edward H. Lambert published the first EMG/NCS diagnostic criteria for ALS, consisting of four findings he considered to strongly support the diagnosis.[129] Since then a number of diagnostic criteria have been developed, which are mostly in use for research purposes for inclusion/exclusion criteria, and to stratify patients for analysis in trials. Research diagnostic criteria for ALS include the "El Escorial" in 1994,[130] revised in 1998.[131] In 2006, the "Awaji" criteria proposed using EMG and NCV tests to help diagnose ALS earlier,[132] and most recently the "Gold Coast" criteria in 2019.[133]

Name[edit]

Amyotrophic comes from Greek: a- means "no", myo- (from mûs) refers to "muscle", and trophḗ means "nourishment". Therefore, amyotrophy means "muscle malnourishment"[134] or the wasting of muscle tissue.[135] Lateral identifies the locations in the spinal cord of the affected motor neurons. Sclerosis means "scarring" or "hardening" and refers to the death of the motor neurons in the spinal cord.[134]

ALS is sometimes referred to as Charcot's disease (not to be confused with Charcot–Marie–Tooth disease or Charcot joint disease), because Jean-Martin Charcot was the first to connect the clinical symptoms with the pathology seen at autopsy.[136] The British neurologist Russell Brain coined the term motor neurone disease in 1933 to reflect his belief that ALS, progressive bulbar palsy, and progressive muscular atrophy were all different forms of the same disease.[137] In some countries, especially the United States, ALS is called Lou Gehrig's disease[126] after the American baseball player Lou Gehrig, who developed ALS in 1938.[138]

In the United States and continental Europe, the term ALS (as well as Lou Gehrig's disease in the US) refers to all forms of the disease, including "classical" ALS, progressive bulbar palsy, progressive muscular atrophy, and primary lateral sclerosis.[139][33] In the United Kingdom and Australia, the term motor neurone disease refers to all forms of the disease while ALS only refers to "classical" ALS, meaning the form with both upper and lower motor neuron involvement.[139]

Society and culture[edit]

A student demonstrating the ice bucket challenge

In addition to the baseball player Lou Gehrig and the theoretical physicist Stephen Hawking (who notably lived longer than any other known person with the condition) a number of other notable individuals have or have had ALS.[65] People with ALS have been featured in high-profile works such as the memoir Tuesdays with Morrie and the critically acclaimed motion picture The Theory of Everything.

In August 2014 the "Ice Bucket Challenge" to raise money for ALS research went viral online.[140] Participants filmed themselves filling a bucket full of ice water and pouring it onto themselves; they then nominated other individuals to do the same. Many participants donated to ALS research at the ALS Association, the ALS Therapy Development Institute, ALS Society of Canada, or Motor Neurone Disease Association in the UK.[141]

References[edit]

Public Domain This article incorporates text from this source, which is in the public domain: "Amyotrophic Lateral Sclerosis Fact Sheet". Archived from the original on 18 November 2004.

  1. ^ a b Wijesekera LC, Leigh PN (February 2009). "Amyotrophic lateral sclerosis". Orphanet Journal of Rare Diseases. 4 (4): 3. doi:10.1186/1750-1172-4-3. PMC 2656493. PMID 19192301.
  2. ^ a b c d e f g h i Masrori P, Van Damme P (October 2020). "Amyotrophic lateral sclerosis: a clinical review". European Journal of Neurology. 27 (10): 1918–1929. doi:10.1111/ene.14393. PMC 7540334. PMID 32526057.
  3. ^ a b c d e f g h i j k l m n o p q r "Amyotrophic Lateral Sclerosis (ALS) Fact Sheet". National Institute of Neurological Disorders and Stroke. Archived from the original on 5 January 2017. Retrieved 22 October 2020.
  4. ^ Kwan J, Vullaganti M (September 2022). "Amyotrophic lateral sclerosis mimics". Muscle & Nerve. 66 (3): 240–252. doi:10.1002/mus.27567. PMID 35607838. S2CID 249014375.
  5. ^ a b c d e f g h i j k l m n o p q r s t u Hobson EV, McDermott CJ (September 2016). "Supportive and symptomatic management of amyotrophic lateral sclerosis" (PDF). Nature Reviews. Neurology. 12 (9): 526–538. doi:10.1038/nrneurol.2016.111. PMID 27514291. S2CID 8547381. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
  6. ^ a b c d e f g h Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, Feldman EL (May 2022). "Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis". The Lancet. Neurology. 21 (5): 480–493. doi:10.1016/S1474-4422(21)00465-8. PMC 9513753. PMID 35334233.
  7. ^ Ryan M, Heverin M, McLaughlin RL, Hardiman O (November 2019). "Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis". JAMA Neurology. 76 (11): 1367–1374. doi:10.1001/jamaneurol.2019.2044. PMC 6646974. PMID 31329211.
  8. ^ "Motor Neuron Diseases Fact Sheet". www.ninds.nih.gov. National Institute of Neurological Disorders and Stroke. Archived from the original on 10 October 2020. Retrieved 27 October 2020.
  9. ^ a b c d e f g h i j k l m n o p van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH (November 2017). "Amyotrophic lateral sclerosis". Lancet. 390 (10107): 2084–2098. doi:10.1016/S0140-6736(17)31287-4. PMID 28552366. S2CID 24483077.
  10. ^ a b c d e f g h i j k l m n o p q r s t u v w Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. (October 2017). "Amyotrophic lateral sclerosis" (PDF). Nature Reviews. Disease Primers. 3 (17071): 17071. doi:10.1038/nrdp.2017.71. PMID 28980624. S2CID 1002680. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
  11. ^ "Understanding ALS". The ALS Association. Archived from the original on 26 October 2020. Retrieved 28 October 2020.
  12. ^ a b Wingo TS, Cutler DJ, Yarab N, Kelly CM, Glass JD (2011). "The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry". PLOS ONE. 6 (11): e27985. Bibcode:2011PLoSO...627985W. doi:10.1371/journal.pone.0027985. PMC 3222666. PMID 22132186.
  13. ^ "Amyotrophic lateral sclerosis". MedlinePlus Genetics. Retrieved 7 August 2023.
  14. ^ a b c d e f g h i j Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, Feldman EL (May 2022). "Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis". The Lancet. Neurology. 21 (5): 465–479. doi:10.1016/S1474-4422(21)00414-2. PMC 9513754. PMID 35334234.
  15. ^ a b "FDA-Approved Drugs for Treating ALS". The ALS Association. Archived from the original on 25 April 2023. Retrieved 25 April 2023.
  16. ^ Heo YA (September 2022). "Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval". CNS Drugs. 36 (9): 1007–1013. doi:10.1007/s40263-022-00945-x. PMID 35907175. S2CID 251162676.
  17. ^ a b c d e f g h i j k l m n Soriani MH, Desnuelle C (May 2017). "Care management in amyotrophic lateral sclerosis". Revue Neurologique. 173 (5): 288–299. doi:10.1016/j.neurol.2017.03.031. PMID 28461024.
  18. ^ a b c d e f g h i j k l Connolly S, Galvin M, Hardiman O (April 2015). "End-of-life management in patients with amyotrophic lateral sclerosis". The Lancet. Neurology. 14 (4): 435–442. doi:10.1016/S1474-4422(14)70221-2. PMID 25728958. S2CID 34109901.
  19. ^ a b c d e f g h i Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. (March 2011). "Amyotrophic lateral sclerosis". Lancet. 377 (9769): 942–955. doi:10.1016/s0140-6736(10)61156-7. PMID 21296405.
  20. ^ a b Pupillo E, Messina P, Logroscino G, Beghi E (February 2014). "Long-term survival in amyotrophic lateral sclerosis: a population-based study". Annals of Neurology. 75 (2): 287–297. doi:10.1002/ana.24096. PMID 24382602. S2CID 205345019.
  21. ^ a b c d e Rowland LP (March 2001). "How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot". Archives of Neurology. 58 (3): 512–515. doi:10.1001/archneur.58.3.512. PMID 11255459.
  22. ^ "8B60 Motor neuron disease". ICD-11 for Mortality and Morbidity Statistics. World Health Organization. Archived from the original on 1 August 2018. Retrieved 24 January 2019.
  23. ^ van Eenennaam RM, Koppenol LS, Kruithof WJ, Kruitwagen-van Reenen ET, Pieters S, van Es MA, et al. (November 2021). "Discussing Personalized Prognosis Empowers Patients with Amyotrophic Lateral Sclerosis to Regain Control over Their Future: A Qualitative Study". Brain Sciences. 11 (12): 1597. doi:10.3390/brainsci11121597. PMC 8699408. PMID 34942899.
  24. ^ a b c d e f g h Grad LI, Rouleau GA, Ravits J, Cashman NR (August 2017). "Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS)". Cold Spring Harbor Perspectives in Medicine. 7 (8): a024117. doi:10.1101/cshperspect.a024117. PMC 5538408. PMID 28003278.
  25. ^ a b Arora RD, Khan YS (2023). "Motor Neuron Disease". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32809609. Retrieved 27 August 2023.
  26. ^ Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J (August 2010). "ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis". Amyotrophic Lateral Sclerosis. 11 (4): 379–382. doi:10.3109/17482960903426543. PMID 20001486. S2CID 27672209.
  27. ^ a b c Swinnen B, Robberecht W (November 2014). "The phenotypic variability of amyotrophic lateral sclerosis". Nature Reviews. Neurology. 10 (11): 661–670. doi:10.1038/nrneurol.2014.184. PMID 25311585. S2CID 205516010. Archived from the original on 31 December 2018. Retrieved 22 August 2018.
  28. ^ a b c Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH (October 2016). "Amyotrophic lateral sclerosis: moving towards a new classification system". The Lancet. Neurology. 15 (11): 1182–1194. doi:10.1016/S1474-4422(16)30199-5. hdl:2318/1636249. PMID 27647646. S2CID 45285510.
  29. ^ Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM (November 2015). "Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis)". Neurologic Clinics. 33 (4): 775–785. doi:10.1016/j.ncl.2015.07.003. PMC 4629514. PMID 26515621.
  30. ^ Zhang H, Chen L, Tian J, Fan D (October 2021). "Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis". BMC Neurology. 21 (1): 405. doi:10.1186/s12883-021-02438-8. PMC 8532334. PMID 34686150.
  31. ^ Lehky T, Grunseich C (November 2021). "Juvenile Amyotrophic Lateral Sclerosis: A Review". Genes. 12 (12): 1935. doi:10.3390/genes12121935. PMC 8701111. PMID 34946884.
  32. ^ Teoh HL, Carey K, Sampaio H, Mowat D, Roscioli T, Farrar M (2017). "Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy". Neural Plasticity. 2017: 6509493. doi:10.1155/2017/6509493. PMC 5467325. PMID 28634552.
  33. ^ a b Tard C, Defebvre L, Moreau C, Devos D, Danel-Brunaud V (May 2017). "Clinical features of amyotrophic lateral sclerosis and their prognostic value". Revue Neurologique. 173 (5): 263–272. doi:10.1016/j.neurol.2017.03.029. PMID 28477850.
  34. ^ Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, et al. (May 2013). "Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14 (Suppl 1): 5–18. doi:10.3109/21678421.2013.778548. PMC 3779649. PMID 23678876.
  35. ^ "Motor neurone disease". UK: National Health Service. 15 January 2018. Archived from the original on 29 December 2014. Retrieved 24 October 2020.
  36. ^ a b Chiò A, Mora G, Lauria G (February 2017). "Pain in amyotrophic lateral sclerosis". The Lancet. Neurology. 16 (2): 144–157. arXiv:1607.02870. doi:10.1016/S1474-4422(16)30358-1. PMID 27964824. S2CID 38905437.
  37. ^ Gromicho M, Figueiral M, Uysal H, Grosskreutz J, Kuzma-Kozakiewicz M, Pinto S, et al. (July 2020). "Spreading in ALS: The relative impact of upper and lower motor neuron involvement". Annals of Clinical and Translational Neurology. 7 (7): 1181–1192. doi:10.1002/acn3.51098. PMC 7359118. PMID 32558369.
  38. ^ Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (October 1999). "The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)". Journal of the Neurological Sciences. 169 (1–2): 13–21. doi:10.1016/s0022-510x(99)00210-5. PMID 10540002. S2CID 7057926.
  39. ^ Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. (2021). "Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective". Brain Communications. 3 (4): fcab242. doi:10.1093/braincomms/fcab242. PMC 8659356. PMID 34901853.
  40. ^ Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A (June 2015). "Prognostic factors for the course of functional status of patients with ALS: a systematic review". Journal of Neurology. 262 (6): 1407–1423. doi:10.1007/s00415-014-7564-8. PMID 25385051. S2CID 31734765.
  41. ^ Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. (November 2014). "The PRO-ACT database: design, initial analyses, and predictive features". Neurology. 83 (19): 1719–1725. doi:10.1212/WNL.0000000000000951. PMC 4239834. PMID 25298304.
  42. ^ a b Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. (March 2016). "How common are ALS plateaus and reversals?". Neurology. 86 (9): 808–812. doi:10.1212/WNL.0000000000002251. PMC 4793781. PMID 26658909.
  43. ^ Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME (2010). "Clinical significance in the change of decline in ALSFRS-R". Amyotrophic Lateral Sclerosis (Journal Article). 11 (1–2): 178–180. doi:10.3109/17482960903093710. PMID 19634063. S2CID 207619689.
  44. ^ a b Yunusova Y, Plowman EK, Green JR, Barnett C, Bede P (2019). "Clinical Measures of Bulbar Dysfunction in ALS". Frontiers in Neurology. 10: 106. doi:10.3389/fneur.2019.00106. PMC 6389633. PMID 30837936.
  45. ^ Lui AJ, Byl NN (June 2009). "A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis". Journal of Neurologic Physical Therapy. 33 (2): 68–87. doi:10.1097/NPT.0b013e31819912d0. PMID 19556916. S2CID 7650356.
  46. ^ Beukelman D, Fager S, Nordness A (2011). "Communication Support for People with ALS". Neurology Research International. 2011: 714693. doi:10.1155/2011/714693. PMC 3096454. PMID 21603029.
  47. ^ Kuzma-Kozakiewicz M, Andersen PM, Ciecwierska K, Vázquez C, Helczyk O, Loose M, et al. (September 2019). "An observational study on quality of life and preferences to sustain life in locked-in state". Neurology. 93 (10): e938–e945. doi:10.1212/WNL.0000000000008064. PMC 6745736. PMID 31391247.
  48. ^ O'Brien D, Stavroulakis T, Baxter S, Norman P, Bianchi S, Elliott M, et al. (September 2019). "The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review". The European Respiratory Journal. 54 (3): 1900261. doi:10.1183/13993003.00261-2019. PMID 31273038. S2CID 195805546.
  49. ^ a b Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, O Brannagáin D, et al. (April 2011). "Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives". Journal of Neurology, Neurosurgery, and Psychiatry. 82 (4): 413–418. doi:10.1136/jnnp.2010.232637. hdl:2262/59035. PMID 21297150. S2CID 7043837. Archived from the original on 28 May 2023. Retrieved 30 April 2023.
  50. ^ Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier N, Seilhean D, et al. (1 January 2008). "Causes of death in a post-mortem series of ALS patients". Amyotrophic Lateral Sclerosis. 9 (1): 59–62. doi:10.1080/17482960701656940. PMID 17924236. S2CID 40367873.
  51. ^ Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Young C, et al. (May 2017). "Comparison of the King's and MiToS staging systems for ALS". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 18 (3–4): 227–232. doi:10.1080/21678421.2016.1265565. PMC 5425622. PMID 28054828.
  52. ^ a b Chiò A, Calvo A, Moglia C, Mazzini L, Mora G (July 2011). "Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 82 (7): 740–746. doi:10.1136/jnnp.2010.235952. PMID 21402743. S2CID 13416164. Archived (PDF) from the original on 24 November 2022. Retrieved 4 August 2022.
  53. ^ Landau E (20 September 2009). "Stephen Hawking serves as role model for ALS patients". CNN. Archived from the original on 15 August 2016.
  54. ^ a b Martin S, Al Khleifat A, Al-Chalabi A (2017). "What causes amyotrophic lateral sclerosis?". F1000Research. 6: 371. doi:10.12688/f1000research.10476.1. PMC 5373425. PMID 28408982.
  55. ^ a b Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. (October 2018). "ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS". Neurology. 91 (15): e1370–e1380. doi:10.1212/WNL.0000000000006317. PMC 6177274. PMID 30209236.
  56. ^ Yang T, Hou Y, Li C, Cao B, Cheng Y, Wei Q, et al. (July 2021). "Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 92 (7): 688–693. doi:10.1136/jnnp-2020-325701. PMID 33563800. S2CID 231858696.
  57. ^ Wicks P (July 2007). "Excessive yawning is common in the bulbar-onset form of ALS". Acta Psychiatrica Scandinavica. 116 (1): 76, author reply 76-76, author reply 77. doi:10.1111/j.1600-0447.2007.01025.x. PMID 17559605. S2CID 12807996.
  58. ^ Sauvé WM (December 2016). "Recognizing and treating pseudobulbar affect". CNS Spectrums. 21 (S1): 34–44. doi:10.1017/S1092852916000791. PMID 28044945. S2CID 21066800.
  59. ^ Raaphorst J, Beeldman E, De Visser M, De Haan RJ, Schmand B (October 2012). "A systematic review of behavioural changes in motor neuron disease". Amyotrophic Lateral Sclerosis. 13 (6): 493–501. doi:10.3109/17482968.2012.656652. PMID 22424127. S2CID 22224140.
  60. ^ Couratier P, Corcia P, Lautrette G, Nicol M, Marin B (May 2017). "ALS and frontotemporal dementia belong to a common disease spectrum". Revue Neurologique. 173 (5): 273–279. doi:10.1016/j.neurol.2017.04.001. PMID 28449882.
  61. ^ a b c Renton AE, Chiò A, Traynor BJ (January 2014). "State of play in amyotrophic lateral sclerosis genetics". Nature Neuroscience. 17 (1): 17–23. doi:10.1038/nn.3584. hdl:2318/156177. PMC 4544832. PMID 24369373.
  62. ^ Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ (June 2016). "The cognitive profile of ALS: a systematic review and meta-analysis update". Journal of Neurology, Neurosurgery, and Psychiatry. 87 (6): 611–619. doi:10.1136/jnnp-2015-310734. PMID 26283685. S2CID 22082109.
  63. ^ a b c d Al-Chalabi A, Hardiman O (November 2013). "The epidemiology of ALS: a conspiracy of genes, environment and time". Nature Reviews. Neurology. 9 (11): 617–628. doi:10.1038/nrneurol.2013.203. PMID 24126629. S2CID 25040863.
  64. ^ a b "Amyotrophic lateral sclerosis (ALS) - Symptoms and causes". Mayo Clinic. Archived from the original on 6 April 2022. Retrieved 6 April 2022.
  65. ^ a b c "Who Gets ALS?". The ALS Association. Archived from the original on 6 April 2022. Retrieved 6 April 2022.
  66. ^ He J, Mangelsdorf M, Fan D, Bartlett P, Brown MA (December 2015). "Amyotrophic Lateral Sclerosis Genetic Studies: From Genome-wide Association Mapping to Genome Sequencing" (PDF). The Neuroscientist. 21 (6): 599–615. doi:10.1177/1073858414555404. PMID 25378359. S2CID 3437565. Archived (PDF) from the original on 7 May 2020. Retrieved 20 December 2019.
  67. ^ McNeill A, Amador MD, Bekker H, Clarke A, Crook A, Cummings C, et al. (June 2022). "Predictive genetic testing for Motor neuron disease: time for a guideline?". European Journal of Human Genetics. 30 (6): 635–636. doi:10.1038/s41431-022-01093-y. PMC 9177585. PMID 35379930.
  68. ^ De Oliveira HM, Soma A, Baker MR, Turner MR, Talbot K, Williams TL (August 2023). "A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 24 (5–6): 405–413. doi:10.1080/21678421.2022.2150556. PMID 36458618. S2CID 254150195.
  69. ^ Müller K, Oh KW, Nordin A, Panthi S, Kim SH, Nordin F, et al. (February 2022). "De novo mutations in SOD1 are a cause of ALS". Journal of Neurology, Neurosurgery, and Psychiatry. 93 (2): 201–206. doi:10.1136/jnnp-2021-327520. PMC 8784989. PMID 34518333.
  70. ^ McNeill A, Amador MD, Bekker H, Clarke A, Crook A, Cummings C, et al. (International Alliance of ALS/MND Associations) (June 2022). "Predictive genetic testing for Motor neuron disease: time for a guideline?". European Journal of Human Genetics. 30 (6): 635–636. doi:10.1038/s41431-022-01093-y. PMC 9177585. PMID 35379930.
  71. ^ Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, van den Berg LH, et al. (May 2022). "The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis". Brain. 145 (4): 1207–1210. doi:10.1093/brain/awab472. PMC 9129091. PMID 35020823. Archived from the original on 27 May 2023. Retrieved 27 May 2023.
  72. ^ a b c Wang MD, Little J, Gomes J, Cashman NR, Krewski D (July 2017). "Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis". Neurotoxicology. 61: 101–130. doi:10.1016/j.neuro.2016.06.015. PMID 27377857. S2CID 33604904. Archived from the original on 17 November 2022. Retrieved 27 May 2023.
  73. ^ a b Grossman AB, Levin BE, Bradley WG (March 2006). "Premorbid personality characteristics of patients with ALS". Amyotrophic Lateral Sclerosis. 7 (1): 27–31. doi:10.1080/14660820510012004. PMID 16546756. S2CID 20998807.
  74. ^ a b c Parkin Kullmann JA, Hayes S, Pamphlett R (October 2018). "Are people with amyotrophic lateral sclerosis (ALS) particularly nice? An international online case-control study of the Big Five personality factors". Brain and Behavior. 8 (10): e01119. doi:10.1002/brb3.1119. PMC 6192405. PMID 30239176.
  75. ^ Mehl T, Jordan B, Zierz S (January 2017). ""Patients with amyotrophic lateral sclerosis (ALS) are usually nice persons"-How physicians experienced in ALS see the personality characteristics of their patients". Brain and Behavior. 7 (1): e00599. doi:10.1002/brb3.599. PMC 5256182. PMID 28127517.
  76. ^ Robberecht W, Philips T (April 2013). "The changing scene of amyotrophic lateral sclerosis". Nature Reviews. Neuroscience. 14 (4): 248–264. doi:10.1038/nrn3430. PMID 23463272. S2CID 208941.
  77. ^ a b c d e f g h Brown RH, Al-Chalabi A (July 2017). "Amyotrophic Lateral Sclerosis". The New England Journal of Medicine. 377 (2): 162–172. doi:10.1056/NEJMra1603471. PMID 28700839. S2CID 205117619. Archived from the original on 25 February 2021. Retrieved 20 December 2019.
  78. ^ Okamoto K, Mizuno Y, Fujita Y (April 2008). "Bunina bodies in amyotrophic lateral sclerosis". Neuropathology. 28 (2): 109–115. doi:10.1111/j.1440-1789.2007.00873.x. PMID 18069968. S2CID 34398467.
  79. ^ White JA, Banerjee R, Gunawardena S (May 2016). "Axonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of Therapeutics". Marine Drugs. 14 (5): 102. doi:10.3390/md14050102. PMC 4882576. PMID 27213408.
  80. ^ Ng Kee Kwong KC, Mehta AR, Nedergaard M, Chandran S (August 2020). "Defining novel functions for cerebrospinal fluid in ALS pathophysiology". Acta Neuropathologica Communications. 8 (1): 140. doi:10.1186/s40478-020-01018-0. PMC 7439665. PMID 32819425.
  81. ^ Van Damme P, Robberecht W, Van Den Bosch L (May 2017). "Modelling amyotrophic lateral sclerosis: progress and possibilities". Disease Models & Mechanisms. 10 (5): 537–549. doi:10.1242/dmm.029058. PMC 5451175. PMID 28468939.
  82. ^ Alsultan AA, Waller R, Heath PR, Kirby J (2016). "The genetics of amyotrophic lateral sclerosis: current insights". Degenerative Neurological and Neuromuscular Disease. 6: 49–64. doi:10.2147/DNND.S84956. PMC 6053097. PMID 30050368.
  83. ^ Shang Y, Huang EJ (September 2016). "Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis". Brain Research. 1647: 65–78. doi:10.1016/j.brainres.2016.03.036. PMC 5003642. PMID 27033831.
  84. ^ Nguyen HP, Van Broeckhoven C, van der Zee J (June 2018). "ALS Genes in the Genomic Era and their Implications for FTD". Trends in Genetics. 34 (6): 404–423. doi:10.1016/j.tig.2018.03.001. hdl:10067/1514730151162165141. PMID 29605155.
  85. ^ Gitler AD, Tsuiji H (September 2016). "There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS". Brain Research. 1647: 19–29. doi:10.1016/j.brainres.2016.04.004. PMC 5003651. PMID 27059391.
  86. ^ Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, et al. (February 2021). "Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis". Acta Neuropathologica. 141 (2): 257–279. doi:10.1007/s00401-020-02252-5. PMC 7847443. PMID 33398403.
  87. ^ Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJ, et al. (2019). "Biomarkers in Motor Neuron Disease: A State of the Art Review". Frontiers in Neurology. 10: 291. doi:10.3389/fneur.2019.00291. PMC 6456669. PMID 31001186.
  88. ^ Joyce NC, Carter GT (May 2013). "Electrodiagnosis in persons with amyotrophic lateral sclerosis". PM&R. 5 (5 Suppl): S89–S95. doi:10.1016/j.pmrj.2013.03.020. PMC 4590769. PMID 23523708.
  89. ^ Silani V, Messina S, Poletti B, Morelli C, Doretti A, Ticozzi N, Maderna L (March 2011). "The diagnosis of Amyotrophic lateral sclerosis in 2010". Archives Italiennes de Biologie. 149 (1): 5–27. doi:10.4449/aib.v149i1.1260. PMID 21412713.
  90. ^ Stickler DE. Lorenzo N (ed.). "Lambert-Eaton Myasthenic Syndrome (LEMS)". Misc.medscape.com. Archived from the original on 14 May 2013. Retrieved 18 April 2013.
  91. ^ "Lambert-Eaton Myasthenic Syndrome: About". LEMS.com. BioMarin Pharmaceutical Inc. Archived from the original on 20 January 2013. Retrieved 18 April 2013.
  92. ^ Mills KR (November 2010). "Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome". Brain. 133 (11): 3458–3469. doi:10.1093/brain/awq290. PMID 20959307.
  93. ^ a b Radunovic A, Annane D, Rafiq MK, Brassington R, Mustfa N (October 2017). "Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease". The Cochrane Database of Systematic Reviews. 10 (10): CD004427. doi:10.1002/14651858.CD004427.pub4. PMC 6485636. PMID 28982219.
  94. ^ a b c d Ahmed RM, Newcombe RE, Piper AJ, Lewis SJ, Yee BJ, Kiernan MC, Grunstein RR (April 2016). "Sleep disorders and respiratory function in amyotrophic lateral sclerosis". Sleep Medicine Reviews. 26: 33–42. doi:10.1016/j.smrv.2015.05.007. PMID 26166297.
  95. ^ a b Eisen A, Krieger C (November 2013). "Ethical considerations in the management of amyotrophic lateral sclerosis". Progress in Neurobiology. 110: 45–53. doi:10.1016/j.pneurobio.2013.05.001. PMID 23735671. S2CID 26282198.
  96. ^ a b Lewis M, Rushanan S (2007). "The role of physical therapy and occupational therapy in the treatment of amyotrophic lateral sclerosis". NeuroRehabilitation. 22 (6): 451–461. doi:10.3233/NRE-2007-22608. PMID 18198431.
  97. ^ a b c d e "Amyotrophic Lateral Sclerosis (ALS)". American Speech-Language-Hearing Association, Rockville, MD. Archived from the original on 2 August 2012. Retrieved 30 November 2016.
  98. ^ a b c Orrell RW (2010). "Motor neuron disease: systematic reviews of treatment for ALS and SMA". British Medical Bulletin. 93: 145–159. doi:10.1093/bmb/ldp049. PMID 20015852.
  99. ^ a b c Arbesman M, Sheard K (2014). "Systematic review of the effectiveness of occupational therapy-related interventions for people with amyotrophic lateral sclerosis". The American Journal of Occupational Therapy. 68 (1): 20–26. doi:10.5014/ajot.2014.008649. PMID 24367951.
  100. ^ a b Sulistyo A, Abrahao A, Freitas ME, Ritsma B, Zinman L (August 2023). "Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease". The Cochrane Database of Systematic Reviews. 2023 (8): CD004030. doi:10.1002/14651858.CD004030.pub4. PMC 10413437. PMID 37579081.
  101. ^ a b c Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. (March 2012). "EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force". European Journal of Neurology. 19 (3): 360–375. doi:10.1111/j.1468-1331.2011.03501.x. PMID 21914052. S2CID 5746940.
  102. ^ a b c d Miller RG, Mitchell JD, Moore DH (March 2012). "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)". The Cochrane Database of Systematic Reviews. 2012 (3): CD001447. doi:10.1002/14651858.CD001447.pub3. PMC 7055506. PMID 22419278.
  103. ^ Carlesi C, Pasquali L, Piazza S, Lo Gerfo A, Caldarazzo Ienco E, Alessi R, et al. (March 2011). "Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis". Archives Italiennes de Biologie. 149 (1): 151–167. doi:10.4449/aib.v149i1.1267. PMID 21412722.
  104. ^ Abe, Koji; et al. (July 2017). "Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial". The Lancet. Neurology. 16 (7): 505–512. doi:10.1016/S1474-4422(17)30115-1. PMID 28522181.
  105. ^ a b c d e Dorst J, Ludolph AC, Huebers A (2018). "Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis". Therapeutic Advances in Neurological Disorders. 11: 1756285617734734. doi:10.1177/1756285617734734. PMC 5784546. PMID 29399045.
  106. ^ Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J (October 2017). "Edaravone and its clinical development for amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 18 (sup1): 5–10. doi:10.1080/21678421.2017.1353101. PMID 28872907.
  107. ^ Center for Drug Evaluation and Research (16 June 2022). "FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)". U.S. Food and Drug Administration. Archived from the original on 12 May 2022. Retrieved 25 April 2023.
  108. ^ "AMX0035 (RELYVRIO)". The ALS Association. Archived from the original on 25 April 2023. Retrieved 25 April 2023.
  109. ^ "ALS drug will be pulled from US market after study showed patients didn't benefit". AP News. 4 April 2024. Retrieved 4 April 2024.
  110. ^ Amylyx Pharmaceuticals Inc. (4 January 2023). A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS) (Report). clinicaltrials.gov.
  111. ^ a b "FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene" (Press release). U.S. Food and Drug Administration (FDA). 25 April 2023. Archived from the original on 25 April 2023. Retrieved 25 April 2023.
  112. ^ Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. (September 2022). "Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS". The New England Journal of Medicine. 387 (12): 1099–1110. doi:10.1056/NEJMoa2204705. PMID 36129998. S2CID 252438252.
  113. ^ Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. (June 2015). "Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis". Neurology. 84 (22): 2247–2257. doi:10.1212/WNL.0000000000001642. PMC 4456658. PMID 25934855.
  114. ^ a b Paganoni S, Karam C, Joyce N, Bedlack R, Carter GT (2015). "Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis". NeuroRehabilitation. 37 (1): 53–68. doi:10.3233/NRE-151240. PMC 5223769. PMID 26409693.
  115. ^ Pinto S, Carvalho M (2014). "Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients". Neurodegenerative Disease Management. 4 (1): 83–102. doi:10.2217/nmt.13.74. PMID 24640982.
  116. ^ Majmudar S, Wu J, Paganoni S (July 2014). "Rehabilitation in amyotrophic lateral sclerosis: why it matters". Muscle & Nerve. 50 (1): 4–13. doi:10.1002/mus.24202. PMC 4433000. PMID 24510737.
  117. ^ Macpherson CE, Bassile CC (July 2016). "Pulmonary Physical Therapy Techniques to Enhance Survival in Amyotrophic Lateral Sclerosis: A Systematic Review". Journal of Neurologic Physical Therapy. 40 (3): 165–175. doi:10.1097/NPT.0000000000000136. PMID 27164308. S2CID 7279853.
  118. ^ Spataro R, Lo Re M, Piccoli T, Piccoli F, La Bella V (September 2010). "Causes and place of death in Italian patients with amyotrophic lateral sclerosis". Acta Neurologica Scandinavica. 122 (3): 217–223. doi:10.1111/j.1600-0404.2009.01290.x. PMID 20078446. S2CID 26479278.
  119. ^ Checkoway H, Lundin JI, Kelada SN (2011). "Chapter 22: Neurodegenerative diseases". In Rothman N, Hainaut P, Schulte P, Smith M, Boffetta P, Perera F (eds.). Molecular Epidemiology: Principles and Practices. International Agency for Research on Cancer. pp. 408–409. ISBN 978-9283221630.
  120. ^ Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA (2013). "Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature". Neuroepidemiology. 41 (2): 118–130. doi:10.1159/000351153. PMC 4049265. PMID 23860588.
  121. ^ Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. (July 2017). "The changing picture of amyotrophic lateral sclerosis: lessons from European registers". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 557–563. doi:10.1136/jnnp-2016-314495. hdl:2318/1633611. PMID 28285264. S2CID 52871105. Archived from the original on 21 December 2019. Retrieved 22 August 2018.
  122. ^ a b c d e Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. (November 2018). "Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015". MMWR. Morbidity and Mortality Weekly Report. 67 (46): 1285–1289. doi:10.15585/mmwr.mm6746a1. PMC 5858037. PMID 30462626.
  123. ^ a b Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ (August 2016). "Projected increase in amyotrophic lateral sclerosis from 2015 to 2040". Nature Communications. 7 (12408): 12408. Bibcode:2016NatCo...712408A. doi:10.1038/ncomms12408. PMC 4987527. PMID 27510634.
  124. ^ a b Luna J, Logroscino G, Couratier P, Marin B (May 2017). "Current issues in ALS epidemiology: Variation of ALS occurrence between populations and physical activity as a risk factor". Revue Neurologique. 173 (5): 244–253. doi:10.1016/j.neurol.2017.03.035. PMID 28477849.
  125. ^ Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP (July 2017). "Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 540–549. doi:10.1136/jnnp-2016-315018. PMID 28057713. S2CID 41974606.
  126. ^ a b Teive HA, Lima PM, Germiniani FM, Munhoz RP (May 2016). "What's in a name? Problems, facts and controversies regarding neurological eponyms". Arquivos de Neuro-Psiquiatria. 74 (5): 423–425. doi:10.1590/0004-282X20160040. PMID 27191240.
  127. ^ Visser J, de Jong JM, de Visser M (February 2008). "The history of progressive muscular atrophy: syndrome or disease?". Neurology. 70 (9): 723–727. doi:10.1212/01.wnl.0000302187.20239.93. PMID 18299524. S2CID 22629725.
  128. ^ Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. (March 2009). "Natural history and clinical features of the flail arm and flail leg ALS variants". Neurology. 72 (12): 1087–1094. doi:10.1212/01.wnl.0000345041.83406.a2. PMC 2821838. PMID 19307543.
  129. ^ Wilbourn AJ (October 1998). "Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria". Journal of the Neurological Sciences. 160 (Supplement 1): S25–S29. doi:10.1016/s0022-510x(98)00194-4. PMID 9851644. S2CID 32884687.
  130. ^ Brooks BR (July 1994). "El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors". Journal of the Neurological Sciences. 124 (Supplement): 96–107. doi:10.1016/0022-510x(94)90191-0. PMID 7807156. S2CID 32678612.
  131. ^ Brooks BR, Miller RG, Swash M, Munsat TL (December 2000). "El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 1 (5): 293–299. doi:10.1080/146608200300079536. PMID 11464847. S2CID 22725949.
  132. ^ de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. (March 2008). "Electrodiagnostic criteria for diagnosis of ALS". Clinical Neurophysiology. 119 (3): 497–503. doi:10.1016/j.clinph.2007.09.143. PMID 18164242. S2CID 14851649.
  133. ^ Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. (August 2020). "A proposal for new diagnostic criteria for ALS". Clinical Neurophysiology. 131 (8): 1975–1978. doi:10.1016/j.clinph.2020.04.005. hdl:10451/48432. PMID 32387049. S2CID 215823371.
  134. ^ a b "What is ALS?". The ALS Association. Archived from the original on 21 December 2018. Retrieved 23 December 2018.
  135. ^ "ALS: Amyotrophic Lateral Sclerosis". Muscular Dystrophy Association. 18 December 2015. Archived from the original on 6 August 2018. Retrieved 23 December 2018.
  136. ^ Goetz CG (March 2000). "Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot". Muscle & Nerve. 23 (3): 336–343. doi:10.1002/(SICI)1097-4598(200003)23:3<336::AID-MUS4>3.0.CO;2-L. PMID 10679709. S2CID 5917354.
  137. ^ Gordon PH (2006). "Chapter 1: History of ALS". In Mitsumoto H, Przedborski S, Gordon PH (eds.). Amyotrophic Lateral Sclerosis. CRC Press. p. 9. ISBN 978-0824729240.
  138. ^ Gordon PH (October 2013). "Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials". Aging and Disease. 4 (5): 295–310. doi:10.14336/AD.2013.0400295. PMC 3794725. PMID 24124634.
  139. ^ a b Huynh W, Simon NG, Grosskreutz J, Turner MR, Vucic S, Kiernan MC (July 2016). "Assessment of the upper motor neuron in amyotrophic lateral sclerosis". Clinical Neurophysiology. 127 (7): 2643–2660. doi:10.1016/j.clinph.2016.04.025. PMID 27291884. S2CID 3757685.
  140. ^ Alexander E (20 August 2014). "George Bush delivers possibly the best ALS ice bucket challenge yet". The Independent. Archived from the original on 21 August 2014. Retrieved 20 August 2014.
  141. ^ Wicks P (December 2014). "The ALS ice bucket challenge - can a splash of water reinvigorate a field?". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15 (7–8): 479–480. doi:10.3109/21678421.2014.984725. PMID 25431828. S2CID 207581186.

External links[edit]

Media related to Amyotrophic lateral sclerosis at Wikimedia Commons